Abstract
The purpose of this study was to investigate whether the overall treatment time and completion rates of chemotherapy were predictive factors for the survival rates in patients with squamous cell carcinoma of the head and neck (SCCHN) who were treated with concurrent chemoradiotherapy (CCRT) using hyperfractionated radiotherapy (RT) and daily carboplatin. The number of intermission days of RT were as follows; 0 (n = 37), 1-5 (n = 8), 6-10 (n = 12) and ≥11 (n = 12), and the days of RT without carboplatin; 0 (n = 27), 1-5 (n = 13), 6-10 (n = 13) and ≥7 (n = 16). The overall treatment time (≤48 vs ≥49 days) was a significant prognostic factor for the local control, disease-free survival and overall survival rates. The completion rate of chemotherapy, as the number of days of RT without carboplatin, was not a significant factor affecting any of the survival rates. In discussion, the strengths of the present study contain that all the patients were treated with 72 Gy delivered as 1.2 Gy twice daily, and received concurrent chemotherapy comprising daily carboplatin as a radio-sensitizer. Based on the results, the completion rate of chemotherapy may have a lower impact on the local control rate in comparison with the overall treatment ...Continue Reading
References
Dec 1, 1992·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·J C HoriotM Bolla
Nov 1, 1990·Cancer·V A MarcialE Vélez-García
Jan 1, 1995·British Journal of Cancer·A J Munro
Jun 1, 1996·International Journal of Radiation Oncology, Biology, Physics·C C WangP Martins
Sep 1, 1996·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Y NishimuraH Kojima
Dec 1, 1996·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·W DuncanD Downing
Jan 10, 1998·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·S HoffstetterP Bey
Jun 19, 1998·The New England Journal of Medicine·D M BrizelL R Prosnitz
Jul 10, 2001·Head & Neck·F LeborgneJ Mezzera
Aug 17, 2002·International Journal of Radiation Oncology, Biology, Physics·Rafal TarnawskiAndrzej Wygoda
May 10, 2003·International Journal of Radiation Oncology, Biology, Physics·Rafal SuwinskiBoguslaw Maciejewski
Nov 16, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J A LangendijkB J Slotman
Feb 2, 2006·BMC Cancer·W BudachK Dietz
Apr 17, 2007·Clinical Oncology : a Journal of the Royal College of Radiologists·N S BeseA Ober
May 1, 2007·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Imjai ChitapanaruxJudith Ford
Jun 23, 2007·Japanese Journal of Clinical Oncology·Mitsuhiko KawashimaTakashi Ogino
Jun 17, 2009·Head & Neck Oncology·Tejpal GuptaKetayun A Dinshaw
Jul 8, 2009·American Journal of Clinical Oncology·Susan A McCloskeyAnurag K Singh
Nov 5, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Phuc Felix Nguyen-TanQuynh-Thu Le